DCT and melanoma: Circulating T-EVs from patients with stage IV melanoma carry a protein signature composed of the melanoma-specific protein tyrosinase-related protein-2 (TYRP2), very late antigen 4 (VLA-4), HSP70, and MET oncoprotein [86].